Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01322815 · ClinicalTrials.gov registry record · Phase 2
A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI
A Phase 2 study, sponsored by Georgetown University.
- Terminated
- Registry status
- Phase 2
- Development phase
- 11
- Enrollment target
NCT01322815 is a Phase 2 study that was terminated before completion, run by Georgetown University. The registered enrollment target is 11 participants.
The verdict
NCT01322815, a Phase 2 study, was terminated before completion, sponsored by Georgetown University.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 11 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time. This study is also being done to measure the immune response to GI-4000. Study drug will be given in addition to a standard of care which is a standard therapy given to patients with your type of cancer (colon).
Interventions
- DRUG chemotherapy and GI-4000
- DRUG GI-4000
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2010-10 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01322815
The ClinicalTrials.gov registry entry for NCT01322815 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Georgetown University, which has 227 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which chemotherapy and GI-4000 is the first listed.
NCT01322815 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01322815 about?
NCT01322815 is a clinical study titled "A Pilot Trial of GI-4000 Plus Bevacizumab and Either FOLFOX or FOLFIRI". The purpose of this study is to test the safety of GI-4000 and see what effects (good and bad) it has against cancer over time. This study is also being done to measure the immune response to GI-4000. Study drug will be given in addition to a standard of care which is a standard therapy given to pat...
What is the current status of trial NCT01322815?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 11 participants. The study started on 2010-10. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01322815?
The interventions under investigation include: chemotherapy and GI-4000 (DRUG), GI-4000 (DRUG).
Who is sponsoring clinical trial NCT01322815?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.